What started as a diabetes medication has rapidly become one of the most talked-about drug categories in modern medicine. GLP-1 medications such as Ozempic, Wegovy, and Mounjaro are already widely known for helping patients lose weight and improve blood sugar control. Now, researchers are uncovering another potentially major benefit: a lower risk of certain cancers and slower tumor progression in some patients.
New studies presented at major cancer conferences suggest GLP-1 medications may be associated with reduced risk involving four major tumor types: colorectal, liver, breast, and lung cancers. While experts stress the research is still evolving, the findings are generating enormous interest because obesity and diabetes are both strongly connected to cancer risk. Here’s what you need to know about the latest developments.
